Skip to content

COvered Balloon Expandable Stent Trial

COvered Balloon Expandable Stent Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN89458845
Enrollment
154
Registered
2006-02-28
Start date
2006-02-20
Completion date
Unknown
Last updated
2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iliac artery occlusive disease Circulatory System Arterial occlusion

Interventions

V12 covered stent versus bare stents. Runoff vessels: The superficial and deep femoral arteries are the runoff vessels for iliac artery procedures, and the tibial arte

Sponsors

Atrium Australia (Australia)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Informed consent obtained 2. Patient aged 18 years or over and under 80 years 3. Patients with TransAtlantic Society Consensus (TASC) type B, C and D lesions 4. Haemodynamically significant dissections after angioplasty 5. Haemodynamically significant recurrent stenosis after angioplasty

Exclusion criteria

Exclusion criteria: 1. Life expectancy of less than 12 months 2. Patients with uncontrolled hypertension 3. Patient with TASC type A lesion 4. Pregnant women or women of childbearing potential who are not following an effective method of contraception 5. Prior enrolment in this trial, patients who had any procedure performed at the aortoiliac level 6. Patients with extensive common femoral artery disease or who have had multiple groin procedures 7. Contradiction to aspirin or clopidogrel usage 8. Patients with superficial and profunda femoral arteries occluded 9. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study, or language barrier such that the subject being unable to give informed consent 10. Uncooperative attitude or potential for non-compliance with the requirements of the protocol making study participation impractical N.B. In patients with a plasma/serum creatinine of more than 250 - 300 µmol/L, iodinated contrast is contraindicated and should be avoided.

Design outcomes

Primary

MeasureTime frame
Comparison, between the two treatment groups (V12 covered stent versus bare stents) of: 1. Primary patency 2. Assisted primary patency

Secondary

MeasureTime frame
Secondary objectives: 1. Any amputation above the ankle 2. Ankle Brachial Index (ABI) changes from baseline

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026